Glucagon in MODY (Maturity Onset Diabetes of the Young)

Investigating Glucagon Secretion in HNF1-alpha and HNF4-alpha MODY

The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose tolerance test (OGTT) before and after omitting their gliclazide medication for 3 days.

Inclusion Criteria:

• Diagnosis of HNF1-alpha or HNF4-alpha MODY.
• Currently on gliclazide treatment

Exclusion Criteria:

• Currently taking any anti-diabetic medication other than gliclazide and metformin
• Oral steroid treatment 30 days prior to the start or at any time during the study period.
• Known malignancy or any other condition or circumstance which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol.
• Felt to be unsuitable to participate in the study in the opinion of the Chief Investigator.
• Currently participating in a clinical trial involving an anti-diabetic medication